TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an announcement.
Ascletis Pharma Inc. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed, including the re-election of directors and the re-appointment of KPMG as auditors. The company granted mandates to the board to issue and repurchase shares, reflecting strong shareholder support and potentially enhancing its capital management strategy.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development and commercialization of innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is listed on the Hong Kong Stock Exchange under the stock code 1672.
Average Trading Volume: 7,167,514
Technical Sentiment Signal: Buy
Current Market Cap: HK$6.11B
See more data about 1672 stock on TipRanks’ Stock Analysis page.